Related Experiment Video
Updated: Oct 25, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development
1Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993,United States.
Human C1-Inhibitor (C1INH) is a key anti-inflammatory protein. Research explores its role beyond Hereditary Angioedema (HAE), investigating C1INH therapies for sepsis, shock, and COVID-19 complications.
Area of Science:
- Biochemistry and Immunology
- Proteinase Inhibitor Research
- Plasma Glycoprotein Function
Background:
- Human C1-Inhibitor (C1INH) is a multifunctional plasma glycoprotein regulating complement, coagulation, and fibrinolytic systems.
- C1INH acts as a major anti-inflammatory agent and interacts with various biological components.
- C1INH deficiency is primarily known for causing Hereditary Angioedema (HAE).
Purpose of the Study:
- To provide an updated overview of C1INH's structure and biological activities.
- To review C1INH's role in HAE pathogenesis and recent therapeutic advancements.
- To explore potential C1INH applications beyond HAE treatment.
Main Methods:
- Literature review of C1INH structure, function, and HAE.
- Analysis of recent research on C1INH therapeutic development.
- Exploration of emerging C1INH applications in other clinical conditions.
Main Results:
- C1INH possesses diverse inhibitory and non-inhibitory functions.
- Significant progress has been made in understanding C1INH deficiency and developing HAE therapies.
- C1INH shows promise for treating conditions like sepsis, endotoxin shock, and COVID-19 complications.
Conclusions:
- C1INH is a critical regulator with broad physiological roles.
- Therapeutic C1INH preparations are being investigated for expanded clinical uses.
- Further research into C1INH's potential beyond HAE is warranted.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:27A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...